Uplizna (inebilizumab)
Provider Summary
Primary Uses
Neuromyelitis optica spectrum disorder (NMOSD) AQP4+ in adults per label/payer criteria.
Mechanism of action
CD19-directed B-cell depletion.
Pre-treatment / baseline requirements
HBV screening and immunoglobulins; screen for TB per clinician; vaccination review; assess infection status prior to infusion; premedication per PI.
Common side effects:
UTI, headache, arthralgia, nausea.
Serious adverse effects / key risks
Serious infections including HBV reactivation; infusion reactions; hypogammaglobulinemia over time.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Neuromyelitis optica spectrum disorder AQP4+ in adults
How it works
Targets CD19 on B-cells to reduce harmful immune activity.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
UTI, headache, arthralgia, nausea.
Get urgent help for
Serious infections including HBV reactivation; infusion reactions; hypogammaglobulinemia over time.
On treatment day
plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.